Last reviewed · How we verify
NCT05769621
A Retrospective Study to Characterize Participants With Propionic Acidemia
trial in Propionic Acidemia in 60 participants. Currently enrolling.
30 September 2026
Quick facts
| Lead sponsor | ModernaTX, Inc. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 16 June 2023 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 September 2026 |
| Sites | 29 locations across France, Italy, Japan, Netherlands, United Kingdom, Canada, Australia, United States |
Conditions studied
- Propionic Acidemia — all drugs for Propionic Acidemia →
Sponsor
ModernaTX, Inc. — full company profile →
Who can join
2 and older, any sex, with Propionic Acidemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a non-interventional, observational, global, multicenter, study describing participant characteristics, clinical outcomes, and event rates in participants with propionic acidemia (PA).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05769621
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Propionic Acidemia
Currently open trials in the same condition.
- NCT05040178 — An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics · recruiting
- NCT05130437 — A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRN · Phase 1, PHASE2 · recruiting
- NCT04159103 — Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia · Phase 1, PHASE2 · recruiting
- NCT04176523 — Understanding the Long-Term Management of Organic Acidemia Patients With CARBAGLU®: A Mixed Methods Approach · recruiting
- NCT02890342 — Natural History, Physiology, Microbiome and Biochemistry Studies of Propionic Acidemia · recruiting
Other ModernaTX, Inc. trials
Trials by the same sponsor.
- NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
- NCT07478952 — A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age · Phase 1 · recruiting
- NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
- NCT07116616 — A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
- NCT07117487 — A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05769621 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ModernaTX, Inc.
- Last refreshed: 5 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05769621.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing